Xeris Biopharma Holdings (XERS) Assets Average (2021 - 2026)

Xeris Biopharma Holdings' Assets Average history runs 6 years deep, the most recent figure standing at $387.8 million for Q1 2026.

• Quarterly Assets Average rose 21.46% year-over-year to $387.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $387.8 million (up 21.46% YoY) and the FY2025 annual result came in at $353.3 million, up 9.44% from the prior year.
• Assets Average was $387.8 million for Q1 2026 at Xeris Biopharma Holdings, up from $376.9 million in the prior quarter.
• Across five years, Assets Average topped out at $387.8 million in Q1 2026 and bottomed at $310.8 million in Q3 2022.
• A 5-year average of $333.5 million and a median of $326.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average surged 48.65% — and 2025, when it declined 3.14%.
• Xeris Biopharma Holdings' Assets Average stood at $323.8 million in 2022, then advanced by 0.44% to $325.2 million in 2023, then decreased by 0.96% to $322.1 million in 2024, then increased by 17.01% to $376.9 million in 2025, then climbed by 2.9% to $387.8 million in 2026.
• Business Quant data shows XERS's Assets Average at $387.8 million in Q1 2026, $376.9 million in Q4 2025, and $352.4 million in Q3 2025.